Medtronic plc (MDT)
Salud / Tecnología médica (dispositivos e implantes)
Diversified medical technology leader across three segments — Cardiovascular (39% of sales), Neuroscience (28%) and Medical Surgical (24%) — plus a retained 90% stake in the Diabetes business (MiniMed), currently being spun off. Recent growth (+8.4% year over year) is inflated by a currency tailwind and a one-time adjustment, neither quantified; normalized to the three-year trajectory, the real pace is closer to 5%. At ~$92 it trades at ~17× adjusted earnings, below the quality med-tech band (16-22×). 5-year base case ~$127 (+10%/year): Fairly valued.
- Price
- $91.80
- Intrinsic value (5y, base)
- $127
- Total annual return (5y)
- 9.6%
- Status (nominal)
- Fairly valued
- Margin of safety
- +20%
The essentials
- Diversified franchise across three medical device segments (Cardiovascular 39% of sales, Neuroscience 28%, Medical Surgical 24%), with a moat built on intellectual property, global scale and regulatory barriers (FDA approvals, the European medical device regulation). Retains ~90% of the Diabetes business (MiniMed) following its partial IPO in March 2026, with the full spin-off expected in the next fiscal year.
- Reported growth in the latest year (+8.4%) was driven, per the company's own disclosure, by the underlying business across most lines plus a currency tailwind and a one-time adjustment in Italy — neither quantified in the filing. The three-year trajectory (+3.6% / +3.6% / +8.4%) points to a more moderate underlying pace; adjusted earnings (company-reported non-GAAP) grew just +0.6% year over year despite the sales increase, pressured by ~$185 million in new tariffs (with further guidance of ~$250 million for the next fiscal year).
- Trades at ~17× adjusted earnings — below the quality med-tech band (16-22×) and well below peers such as Stryker (~21×) or Abbott (~25× forward). 5-year base case ~$127/share (+10%/year): Fairly valued. Aggregate return on invested capital (~7%) falls short of the 10% bar, though incremental return (~13%) and the cash backing of earnings (~10%) are better.
Intrinsic value — two valuation methods
Total return at 5 years: 9.6%/year = 6.7% appreciation + 2.9% dividend. The target price ($127) is ex-dividend; the $15 in dividends collected over 5 years are added separately.
By both methods, the value today (DCF $158 · Multiples $115) exceeds the market price ($92).
Pillars of the analysis
The verdict — today vs 5 years
Today — fairly valued: at $92 trades ~20.4% below its value discounted to today (~$115); the discount is positive but does not reach the margin of safety we require (≥38%).
At 5 years — En valor: the target price ($127) plus dividends yield between the 4% floor and the 10% average return — a reasonable return, though without the margin of a great investment.
The bridge: the return at 5 years exceeds the risk-free rate (4.5%) — but the discount does not reach the required margin of safety (≥38%). To require a 15% annual return, it would need to be bought at ~$73.
Thesis
The business
Medtronic is a diversified medical technology leader across three segments — Cardiovascular (39% of sales, +12% year over year), Neuroscience (28%, +4%) and Medical Surgical (24%, +5%) — plus a retained ~90% stake in the Diabetes business (MiniMed), partially spun off via an IPO in March 2026. The moat combines intellectual property, global scale and regulatory barriers, with a stable direction. Aggregate return on invested capital (~7%) falls short of the 10% bar, weighed down by goodwill inherited from past acquisitions; incremental return (~13%) and the cash backing of earnings (~10%) are better.
The valuation
A diversified med-tech company is valued on a P/E basis over company-reported non-GAAP adjusted earnings — which expenses the amortization of acquisition-related intangibles, restructuring and litigation charges, and the one-time tax effect of an intellectual property transfer between jurisdictions — within the quality med-tech reference band (16-22×). At ~$92 it trades at ~17×, below that band and well below peers such as Stryker or Abbott.
The base case normalizes the revenue starting pace at ~5% (the average of the real three-year trajectory, not the reported +8.4% of the latest year, inflated by a currency tailwind and a one-time adjustment in Italy that goes unquantified), decelerating slightly toward ~4.4% by year 5. Adjusted earnings compound at ~5.6%/year and the exit multiple (17.5×) sits within the band, at the low end. That gives ~$127/share over five years → a total return of +10%/year.
The margin of safety
It trades close to intrinsic value, far from the required margin of safety. At ~$92 Medtronic trades at ~17× adjusted earnings, below the quality med-tech band — part of the discount reflects real, quantified factors (new tariffs, unresolved tax litigation, the ongoing Diabetes/MiniMed spin-off) and part reflects an aggregate return on invested capital below the 10% bar. The verdict is Fairly valued: a diversified, reasonably good-quality business, at a price that already discounts much — though not all — of the known risks.
What to watch
Three things. The transfer-pricing tax litigation with the U.S. tax authority (remanded again to the tax court in September 2025) — nearly two decades unresolved; an adverse ruling would, per the company's own disclosure, have a material impact. Tariffs: the guidance of ~$250 million in additional impact for the next fiscal year, and whether the company manages to mitigate them or they become a permanent structural cost. And the Diabetes/MiniMed spin-off — the company retains ~90% after the partial IPO, with no guaranteed timeline for the full separation — worth watching whether the value of the retained stake holds up or the process runs into complications.
Educational / informational. Does not constitute investment advice.